# CJC-1295 References: The Cited Literature, Indexed

> CJC-1295 references: every study cited across this digest — Teichman 2006, Jette 2005, Ionescu & Frohman 2006, Alba 2006 and more — with DOIs and PubMed links.

Every study cited across this site, with journal, year, DOI and PubMed link. The human pharmacokinetic core, the preclinical work, the structural and analytical papers, and the recent reviews.

## How this CJC-1295 reference list is organized

This is the full citation register for the CJC-1295 digest. Every quantitative claim on this site — every half-life, percentage, fold-change, dose and species — resolves to a numbered entry below. The core human pharmacokinetics rests on two papers from the Frohman lab (Teichman 2006 and Ionescu & Frohman 2006); the preclinical case rests on the Jette 2005 albumin-bioconjugate identification and the Alba 2006 GHRH-knockout-mouse growth study. The remaining entries cover the receptor structural biology, the proteomic and analytical work, the foundational GHRH pharmacology, and the recent reviews that place CJC-1295 within the broader GHRH-analog landscape.

Each entry carries a DOI or PubMed identifier so the source can be checked directly. One registry note: chemical databases disagree on the exact molecular formula for the DAC peptide, a discrepancy flagged in the record rather than resolved here. The list is the spine of the site — nothing is asserted above that is not logged below.

## References

[1] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[2] Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. https://pubmed.ncbi.nlm.nih.gov/15817669/
[3] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/
[4] Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. https://pubmed.ncbi.nlm.nih.gov/16822960/
[5] Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. https://pubmed.ncbi.nlm.nih.gov/19386527/
[6] Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. https://doi.org/10.1002/dta.233
[7] Zhou F, Zhang H, Cong Z, et al. Structural basis for activation of the growth hormone-releasing hormone receptor. Nat Commun. 2020;11(1):5205. https://pubmed.ncbi.nlm.nih.gov/33060564/
[8] Growth hormone-releasing factor-sensitive adenylate cyclase system of purified somatotrophs. (GHRH-sensitive adenylate cyclase characterization). 1989. PMID 2562826. https://pubmed.ncbi.nlm.nih.gov/2562826/
[9] Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and potency. (D-Ala2 GHRH analog study). 1994. PMID 7962295. https://pubmed.ncbi.nlm.nih.gov/7962295/
[10] Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea kinetics. (GH/secretagogue nitrogen-balance study). Growth Horm IGF Res. 2009. PMID 19231263. https://pubmed.ncbi.nlm.nih.gov/19231263/
[11] Modified GRF (1-29) — chemical and pharmacological description. Encyclopedic reference (no-DAC tetrasubstituted GHRH(1-29) vs CJC-1295 DAC). https://en.wikipedia.org/wiki/Modified_GRF_(1-29)
[12] Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. https://pubmed.ncbi.nlm.nih.gov/39537825/
[13] Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev Endocr Metab Disord. 2025. PMID 39934495. https://pubmed.ncbi.nlm.nih.gov/39934495/
[14] Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal conditions. Sports Med. 2026. PMID 41966639. https://pubmed.ncbi.nlm.nih.gov/41966639/
[15] A 2024 update on growth hormone deficiency syndrome in adults: from guidelines to clinical practice. J Clin Med. 2024;13(20):6079. https://pubmed.ncbi.nlm.nih.gov/39458028/

---

An emerald-on-black console reading of the CJC-1295 record — the four substitutions, the DAC albumin handle, and the multi-day-versus-short-acting half-life each logged to its study and split by form, with no clinic behind the panel and nothing here dispensed or sold.